CORT, Piper Jaffray initiates coverage on Corcept Therapeutics ( NASDAQ : CORT ) with an Overweight rating. Price target of 4 dollars. Stock was up 10.13% today to 1.63,after this rating yesterday Janney starts Corcept with Buy rating and fair value of 3 dollars. Manny